Thomas Heineman, MD, PhD profile page

Biography: Dr. Thomas Heineman began his time at Oncolytics as Global Head of Clinical Development and Operations in August 2020 and was promoted to Chief Medical Officer in December 2021. Prior to joining Oncolytics, he was Senior Vice President and Head of Clinical Development at Denovo Biopharma. before his time at Denovo, he served as Vice President and Head of Clinical Development at both Genocea Biosciences and Halozyme Therapeutics. At Halozyme, Dr. Heineman was also Head of Translational Medicine and oversaw clinical trials in indications such as breast and pancreatic cancer. Dr. Heineman’s experience further extends to big pharma and academia, as he previously worked as Senior Director, Global Clinical Research and Development at GlaxoSmithKline and as an Associate Professor at the Saint Louis University School of Medicine. Dr. Heineman has co-authored over 60 peer-reviewed publications and is board certified in Internal Medicine and Infectious Diseases. He completed his fellowship in Infectious Diseases at the National Institutes of Health and his internship and residency at the University of Maryland. Dr. Heineman earned his MD and PhD in Virology at the University of Chicago.